title: Drug delivery systems for oestrogenic hormones and antagonists: the need for selective targeting in estradiol-dependent cancers.
abstract: The pleiotropic activity of oestrogens and their mechanism of action via their binding to the two oestrogen receptors alpha (ER alpha) and beta (ER beta) subtypes in the different tissues where oestrogens exert their action have been briefly described. The fate of these compounds trapped into different galenic forms is discussed with regard to their therapeutic applications. Firstly, the advantages and disadvantages of the different forms (pills, i.v. forms and transdermal patches) used in contraception are compared. Secondly, the therapeutic use of formulated oestrogens for the post-menopausal hormone replacement therapy (HRT) is analysed through the various results obtained in different trials. The link between HRT and the risks of breast cancer and cardiovascular disease is underlined. Finally, comparing the activity of selective oestrogen receptor modulators such as tamoxifen and pure anti-oestrogens such as RU58668 and ICI182780, we analysed the reasons leading to the need for a tumor targeting of the latters, but not of the former for the treatment of oestrogen-dependent breast cancer. Different injectable and biodegradable formulations, that lead to a remarkable anti-tumor efficiency in xenografts, have been recently developed and we believe that they may represent promising new administration ways of added therapeutic values for anti-oestrogens. Such devices could be extended to the delivery of other anti-cancer drugs with more aggressive activities than anti-oestrogens.
authors.affiliation: UMR CNRS 8612, Department of Pharmacologie Cellulaire et Moléculaire des Anticancéreux, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry, France.
authors.forename: Thibault
authors.initials: T
authors.lastname: Ameller
authors.forename: Philippe
authors.initials: P
authors.lastname: Legrand
authors.forename: Véronique
authors.initials: V
authors.lastname: Marsaud
authors.forename: Jack-Michel
authors.initials: JM
authors.lastname: Renoir
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D003267:Contraception; D016503:Drug Delivery Systems; D004965:Estrogen Antagonists / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D004967:Estrogens / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D004967:Estrogens